After Sanofi leadership telegraphed an upsized appetite for business development last month, signals have emerged that the ...
Novartis is gearing up to defend its growth trajectory against a steep wave of patent expirations in the early 2030s, as the ...
The FDA has slammed Johnson & Johnson over misleading claims about its bladder cancer drug Inlexzo, accusing the pharma ...
Biogen is visualizing life amid disease progression in its newest Friedreich ataxia (FA)-focused campaign, reminding ...
Underscoring how crowded the U.S. market for generalized myasthenia gravis (gMG) has become, the FDA on Wednesday approved ...
Lotte Biologics, a South Korea-headquartered CDMO established in 2022, has inked a large manufacturing deal with an unnamed ...
Salerno Pharmaceuticals of Tulsa, Oklahoma, is facing pressure from the FDA to yank its lone commercial product. | In a ...
After delaying the phase 3 readout of its Alzheimer’s psychosis program for Cobenfy earlier this year, Bristol Myers Squibb ...
Beren Therapeutics has officially seen a cyclodextrin therapy across the finish line, scoring an FDA approval in Niemann-Pick disease type C (NPC) that’s over a decade in the making.
No breast cancer asset in Roche’s pipeline carries a higher valuation than giredestrant. | Roche’s giredestrant took the ...
The White House is reportedly pulling the nomination for Heidi Overton, M.D., Ph.D., to lead the FDA just hours before the ...
In a complete response letter (PDF) dated Nov. 13 and newly published on the FDA’s website, reviewers at the agency flagged ...